Point72 Europe London LLP Decreases Stake in Becton, Dickinson and Company (NYSE:BDX)

Point72 Europe London LLP lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 37.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,757 shares of the medical instruments supplier’s stock after selling 25,800 shares during the quarter. Point72 Europe London LLP’s holdings in Becton, Dickinson and Company were worth $9,993,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. WR Wealth Planners LLC boosted its stake in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC lifted its stake in shares of Becton, Dickinson and Company by 1.5% during the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after buying an additional 43 shares during the period. Key Client Fiduciary Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 2.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after buying an additional 43 shares during the last quarter. Clear Creek Financial Management LLC increased its position in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after acquiring an additional 44 shares during the period. Finally, Edge Capital Group LLC raised its stake in Becton, Dickinson and Company by 3.1% in the 4th quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 48 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Evercore ISI cut their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Stock Performance

BDX opened at $236.95 on Wednesday. The firm has a fifty day moving average price of $235.81 and a 200 day moving average price of $235.49. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The stock has a market cap of $68.48 billion, a P/E ratio of 52.19, a P/E/G ratio of 1.91 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the prior year, the company posted $2.96 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.60%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.